107 related articles for article (PubMed ID: 32400078)
1. The point mutation analysis of Cyp2C9
Golshekan E; Sohrabi A
J Cell Physiol; 2020 Dec; 235(12):9317-9322. PubMed ID: 32400078
[TBL] [Abstract][Full Text] [Related]
2. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
Ivashchenko D; Rusin I; Sychev D; Grachev A
Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.
Yang J; Chen Y; Li X; Wei X; Chen X; Zhang L; Zhang Y; Xu Q; Wang H; Li Y; Lu C; Chen W; Zeng C; Yin T
Int J Cardiol; 2013 Oct; 168(4):4234-43. PubMed ID: 23932037
[TBL] [Abstract][Full Text] [Related]
4. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
5. Frequency Distribution of CYP2C9 and VKORC1 Mutations among Bulgarian Patients and their Importance for Anticoagulant Therapy.
Velizarova M; Abedinov P; Svinarov D; Nikolov V; Hristova J
Clin Lab; 2022 Dec; 68(12):. PubMed ID: 36546741
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
Farzamikia N; Sakhinia E; Afrasiabirad A
Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
8. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
Azzam H; Elwakeel H; Awad I; El-Farahaty R; El-Gilany AH; El-Sharawy S
Blood Coagul Fibrinolysis; 2016 Mar; 27(2):121-6. PubMed ID: 24978953
[TBL] [Abstract][Full Text] [Related]
9. Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
Fereidouni M; Moossavi M; Kazemi T; Nouranihassankiade S; Asghari A
J Cell Biochem; 2019 Jun; 120(6):9588-9593. PubMed ID: 30525241
[TBL] [Abstract][Full Text] [Related]
10. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
[TBL] [Abstract][Full Text] [Related]
11. Association between Vitamin K Epoxide Reductase (VKORC1) -1639G>A Polymorphism and Osteoporosis in Postmenopausal Women.
Kutluturk F; Inanir A; Rustemoglu A; Kaya SU; Demir AK; Dursun G; Yigit S
Endocr Metab Immune Disord Drug Targets; 2018; 18(3):281-286. PubMed ID: 29437025
[TBL] [Abstract][Full Text] [Related]
12. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
13. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
14. Significant association between IL10-1082/-819 and TNF-308 haplotypes and the susceptibility to cervical carcinogenesis in women infected by Human papillomavirus.
Chagas BS; Lima RCP; Paiva Júnior SSL; Silva RCO; Cordeiro MN; Silva Neto JDC; Batista MVA; Silva AJD; Gurgel APAD; Freitas AC
Cytokine; 2019 Jan; 113():99-104. PubMed ID: 29935877
[TBL] [Abstract][Full Text] [Related]
15. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.
Brunner-Ziegler S; Jilma B; Magirr D; Sunder-Plassmann R; Giurgea GA; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
Br J Haematol; 2014 Nov; 167(4):547-53. PubMed ID: 25142093
[TBL] [Abstract][Full Text] [Related]
16. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
Kalpana SR; Bharath G; Manjunath CN; Christopher R
Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
[TBL] [Abstract][Full Text] [Related]
17. Improvements in CYP2C9 Genotyping Accuracy Are Needed: A Report of the First Proficiency Testing for Warfarin-related CYP2C9 and VKORC1 Genotyping in China.
Lin G; Yi L; Zhang K; Sun Y; Wang L; Zhang R; Xie J; Li J
J Cardiovasc Pharmacol; 2015 Aug; 66(2):129-34. PubMed ID: 25815675
[TBL] [Abstract][Full Text] [Related]
18. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.
Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A
Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Sehgal T; Hira JK; Ahluwalia J; Das R; Vijayvergiya R; Rana SS; Varma N
Drug Discov Ther; 2015 Dec; 9(6):404-10. PubMed ID: 26781925
[TBL] [Abstract][Full Text] [Related]
20. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
Zhuang W; Wu D; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
